Studies | EBMT

Top

Study type

Disease

Group

Type of transplant / Cell therapy

Text

Language

Disease-specificity effects of HLA mismatching effects in unrelated HCT under with PTCy-based GvHD prophylaxis

Retrospective Studies

Acute Lymphatic Leukaemia (ALL)

Acute Myeloid Leukaemia (AML)

Chronic Lymphocytic Leukaemia (CLL)

Chronic Myeloid Lymphoma (CML)

Chronic Lymphocytic Leukaemia (CLL)

Myelodysplastic (MDS) or MDS/MPN

Other myeloid or lymphoid malignancies

Multiple Myeloma (MM) or other Plasma Cell Disorder (PCD)

Non-Hodgkin’s Lymphoma (NHL)

Cellular Therapy & Immunobiology Working Party (CTIWP)

Acute Leukemia Working Party (ALWP)

Type of treatment

Allogeneic - Unrelated

Principal investigator

Frequency and Impact of Pre-Transplant Somatic Co-Occurring Mutations on Clinical Outcomes of Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation: On Behalf of the EBMT Acute Leukemia Working Party

Retrospective Studies

Acute Myeloid Leukaemia (AML)

Acute Leukemia Working Party (ALWP)

Type of treatment

Principal investigator

Long term outcomes and relative mortality in survivors of allogeneic hematopoietic cell transplantation in acute myeloid leukemia: an analysis from the ALWP of the EBMT

Retrospective Studies

Acute Myeloid Leukaemia (AML)

Acute Leukemia Working Party (ALWP)

Type of treatment

Principal investigator

Outcome of patients with Intermediate risk Acute Myelogenous Leukemia in first remission and no detectable residual disease (MRD negative) transplanted with a haploidentical donor versus autografted

Retrospective Studies

Acute Myeloid Leukaemia (AML)

Acute Leukemia Working Party (ALWP)

Type of treatment

Principal investigator

Norbert-Claude GORIN

Comparison of outcomes after unrelated double-unit cord blood and haploidentical peripheral blood stem cell transplantation in adults with acute myeloid leukemia, a study on behalf of Eurocord and ALWP-EBMT

Retrospective Studies

Acute Myeloid Leukaemia (AML)

Acute Leukemia Working Party (ALWP)

Type of treatment

Allogeneic - Haploidentical

Principal investigator

Annalisa Ruggeri

The role of measurable residual disease (MRD) at the time of allogeneic stem cell transplantation in patients with AML in CR transplanted from unrelated donors with Post transplant cyclophosphamide

Retrospective Studies

Acute Myeloid Leukaemia (AML)

Acute Leukemia Working Party (ALWP)

Type of treatment

Principal investigator

PTCY MMUD vs Haplo in active disease for AML

Retrospective Studies

Acute Myeloid Leukaemia (AML)

Acute Leukemia Working Party (ALWP)

Type of treatment

Allogeneic - Haploidentical

Principal investigator

Frédéric Baron

Trends in non sibling donor in HSCT CR2

Retrospective Studies

Acute Leukemia Working Party (ALWP)

Type of treatment

Allogeneic - Haploidentical

Principal investigator

Trends in donor characteristics for unrelated Stem Cell Transplantation in patients with acute myeloid leukemia

Retrospective Studies

Acute Myeloid Leukaemia (AML)

Acute Leukemia Working Party (ALWP)

Type of treatment

Principal investigator

Haploidentical versus matched sibling donors hematopoietic stem cell transplantation for adult patients with relapsed/refractory acute lymphoblastic leukemia

Retrospective Studies

Acute Lymphatic Leukaemia (ALL)

Acute Leukemia Working Party (ALWP)

Type of treatment

Allogeneic - Haploidentical

Principal investigator

Trends in allogeneic stem cell transplantation (HSCT) over two decades in patients with secondary acute myelogenous leukemia (sAML) being transplanted from sibling (MSD) or unrelated donors (UD). A Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Retrospective Studies

Acute Myeloid Leukaemia (AML)

Acute Leukemia Working Party (ALWP)

Type of treatment

Principal investigator

COLLECTION OF NEXT-GENERATION SEQUENCING (NGS) DATA AND USE OF NOVEL DRUGS IN ACUTE LEUKEMIA PATIENTS

Retrospective Studies

Acute Lymphatic Leukaemia (ALL)

Acute Myeloid Leukaemia (AML)

Acute Leukemia Working Party (ALWP)

Type of treatment

Principal investigator